您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > KRH-3955 hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
KRH-3955 hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
KRH-3955 hydrochloride图片
CAS NO:2253744-59-9
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
KRH-3955 hydrochloride 是一种具有口服活性的CXCR4拮抗剂。KRH-3955 hydrochloride 抑制 SDF-1α 与CXCR4的结合,IC50为0.61 nM。KRH-3955 hydrochloride 也是高效的、选择性的X4 HIV-1抑制剂,EC50为 0.3 至 1.0 nM。
生物活性

KRH-3955 hydrochloride is an orally bioavailableCXCR4antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding toCXCR4with anIC50of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor ofX4HIV-1, with anEC50of 0.3 to 1.0 nM[1].

IC50& Target[1]

X4 HIV-1NL4-3

0.3-1.0 nM (EC50)

SDF-1α-CXCR4

0.61 nM (IC50)

体外研究
(In Vitro)

KRH-3955 inhibits the replication of NL4-3 in activated peripheral blood mononuclear cells (PBMCs) from eight different donors with the EC50ranging from 0.23 to 1.3 nM[1].
KRH-3955 inhibits the infection of CD4/CXCR4 cells by these recombinant drug-resistant viruses, including viruses resistant to PIs, NRTIs, or NNRTIs, multidrug-resistant viruses and T20-resistant viruses, with the IC50ranging from 0.4 to 0.8 nM[1].
KRH-3955 (10-100 nM) inhibits the SDF-1α-induced increase in the intracellular Ca2+concentration in a dose-dependent manner[1].
KRH-3955 (0.1-1000 nM) binding sites are located in a region composed of all three extracellular loops (ECLs) of CXCR4[1].
KRH-3955 (10 nM) has a strong binding affinity for CXCR4 and a slow dissociation rate[1].
KRH-3955 inhibits MAb 12G5 binding to CXCR4 mutants, with the IC50ranging from 0.5 to 14.1 nM[1].

体内研究
(In Vivo)

KRH-3955 (10 mg/kg; a single p.o.) efficiently suppresses X4 HIV-1 infection in hu-PBL-SCID mice[1].
KRH-3955 (10 mg/kg; a single p.o.) exhibits moderate oral bioavailability (25.6%) and Cmax(86.3 ng/mL)[1].
KRH-3955 (10 mg/kg; a single i.v.) exhibits terminal elimination half-lives (99 h) due to high plasma clearance (3.9 liters/h/kg) combined with large volumes of distribution (374 liters/kg)[1].

Animal Model:C.B-17 SCID mice engrafted with human PBMCs and injected with infectious X4 HIV-1 (NL4-3)[1]
Dosage:10 mg/kg
Administration:A single p.o. administration
Result:Four of five mock-treated mice were infected whereas only one of five mice treated with KRH-3955 was infected.
Animal Model:Male Sprague-Dawley rats[1]
Dosage:10 mg/kg (Pharmacokinetic Analysis)
Administration:A single p.o. or i.v. administration
Result:Well absorbed and the absolute oral bioavailability in rats was calculated to be 25.6%.
The half time (T1/2) of 99.0±13.1 h.
Stable in human hepatic microsomes, and no significant inhibition of CYP450 liver enzymes by this compound was observed.
分子量

589.09

Formula

C28H48Cl3N7

CAS 号

2253744-59-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.